Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
about
Biofilm induced tolerance towards antimicrobial peptidesEfficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysisIn vivo therapeutic efficacy and pharmacokinetics of colistin sulfate in an experimental model of enterotoxigenic Escherichia coli infection in weaned pigsRapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data.Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin.Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections.Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect.Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.Multidrug resistant acinetobacter.Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort studyDetermination of the spatiotemporal dependence of Pseudomonas aeruginosa biofilm viability after treatment with NLC-colistin.Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.Colistin in the 21st century.Prevalence of 16S rRNA methylase genes among β-lactamase-producing Enterobacteriaceae clinical isolates in Saudi ArabiaPhosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system.Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.Structure--activity relationships of polymyxin antibioticsColistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients.Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumanniiAntibiotics and bacterial resistance in the 21st century.Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii.Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in micePolymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England.The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice.Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patientsClinical and microbiological features of Providencia bacteremia: experience at a tertiary care hospital.Melatonin attenuates colistin-induced nephrotoxicity in rats.Dosing of colistin-back to basic PK/PD.Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.How to treat VAP due to MDR pathogens in ICU patients.Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingSynergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?
P2860
Q27301462-BD809D58-C3E3-43A2-BCC9-FAD6D3EEC8C8Q28539496-8917C7FC-68C2-4886-A178-4E4B445BFBDAQ28829927-FC92EB3F-061D-4E52-8D3E-FD0A15C4C5FBQ31031386-FBDACD11-5BC8-409A-B45E-BF03CDEC6157Q31071398-57201A7C-1E0E-4B98-9F03-061F8203D695Q33236778-D8B8AF3D-04E0-401C-8740-1671725C6A02Q33416170-442FC9F6-F9EE-4D4E-9F4B-1C4E47B08053Q33532335-9FF64A99-7778-4706-AD56-F0BA44E47AAEQ33662378-7DC60471-85C4-48AE-BCA6-F51CD8934AA5Q33711902-F10EDC3A-7778-4C79-BAD6-55E933249622Q33751736-C720BB19-484C-40E9-9A22-F56218D26B27Q33812561-F00DF4B3-7F6F-46E3-ACE2-FA0F5D3384C5Q33826267-2ED1B149-5283-4E55-98EF-C706FC0D7AC3Q33847509-E08B9065-32AD-4E06-B921-7F00B190DEA0Q33865141-68CE9A9D-2A3C-4C32-9866-D4457B02ACEBQ33901939-E8020906-93B4-4F8E-B097-D6B316DFA348Q33938143-4F184133-73E4-407C-9821-FB2DC7F07C33Q34010143-D36E94FD-C228-4E71-AD1D-960707CF5125Q34015375-7E85F026-C79D-4451-81EA-4FFA5D3DBEDAQ34049982-35CC75CA-001A-49BC-809B-5943EF224656Q34156349-C5854A7E-8549-4332-A546-0F248C6CDD89Q34309445-1040A288-6546-4DD8-93B0-D4656EFC6E83Q34346283-F5793836-4D86-4160-A76A-7B5A62EF1839Q34529241-3BF19E41-F1CF-4FD1-9B99-2BD0F4764092Q34552966-A3BA9841-862E-48DB-A929-CC3F887DA271Q34571574-C9439AE1-E5E1-4751-A11F-9BF1B604D3CBQ34652418-0EEDDD6C-B6ED-4084-91F4-7AABEF71E201Q34675017-BED20779-C684-4311-94EB-AE723518A7B5Q34680516-30976A81-E0A4-4D08-8813-3B6A07044CDEQ35023321-F83C4B1A-C3EF-4B70-B815-963D34C154E0Q35065863-788F3CE3-35C3-4012-B424-EC1B693C3A97Q35152658-EEABA06E-35EF-4226-A09B-D8495417A5CEQ35191353-7117F208-5E68-45A3-A65B-2CDB81711F42Q35242165-157626BD-D852-41F2-8ACC-C2E69868ED96Q35364351-C04FA82E-FE74-4147-A7C7-FBB75EF3E860Q35432770-04C53554-B4CF-4490-A66D-22A1F61F279AQ35457068-4503C0B3-F3FB-4302-9A12-C12122477113Q35541277-5A91834F-1C7A-4C56-8321-42C0F8C0C6A7Q35598403-C57A4C3A-B5E2-47D0-A534-33F58993E63FQ35617587-27F1C200-BE3B-4E2E-AD53-9ED20D59A64C
P2860
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
@ast
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
@en
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
@nl
type
label
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
@ast
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
@en
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
@nl
prefLabel
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
@ast
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
@en
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
@nl
P2093
P1476
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
@en
P2093
John D Turnidge
Kingsley Coulthard
Robert W Milne
Roger L Nation
P356
10.1016/J.IJANTIMICAG.2004.10.001
P577
2005-01-01T00:00:00Z